Tirzepatide Research
Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA
Nature Medicine·March 1, 2026
A. Malhotra, R. Grunstein, A. Azarbarzin, et al.
Summary
Tirzepatide associated with greater alleviation of cardiometabolic risk factors. VLDL-C reduced ~32%, fasting insulin ~43%, HOMA-IR ~51% vs placebo. Treating both OSA and obesity required for optimal benefits.
Study Details
Study Design
Secondary outcomes analysis of phase 3 RCT
Indication
OSA-related cardiometabolic risk
Intervention
Tirzepatide vs placebo for 52 weeks
Species
Human